Fellow Health has completed a $24 million Series B funding round to accelerate expansion of its male reproductive health services, bringing the company’s total capital raised to $48 million since inception.
The financing was spearheaded by 5AM Ventures, with additional investment from The Forest Road Company. The capital injection follows the company’s earlier Series A round and subsequent follow-on funding.
Laboratory Services and Clinical Reach
The company operates a CLIA-certified laboratory that specialises in mail-in semen analysis, vasectomy verification testing, and cryopreservation services. Fellow Health has established partnerships with more than 1,800 clinical practices across the United States, processing over 400 patient specimens daily through its centralised facility.
The laboratory’s testing protocol delivers clinically validated results within two business days of specimen receipt, combining convenience with peer-reviewed diagnostic accuracy. This approach addresses traditional barriers to male fertility assessment, which often requires multiple clinic visits and extended waiting periods.
Growth Trajectory and Market Strategy
Fellow Health plans to deploy the fresh capital towards expanding its mail-in testing capabilities and growing its network of clinical partners. The company is targeting enhanced fertility screening services alongside post-vasectomy monitoring programmes.
According to company data, Fellow Health is tracking towards 40% year-over-year revenue growth, with management projecting profitability in its fertility testing segment by 2026. This growth comes as demand for at-home healthcare solutions continues to rise across multiple medical specialties.
“Male reproductive health should not be reactive or inaccessible,” said Brian Hogan, chief executive of Fellow Health.
The executive added that the investment enables the company to scale its vision whilst supporting both patients and healthcare providers with modern diagnostic tools.
Competitive Landscape
Fellow Health operates within an increasingly active male fertility market. Earlier this year, Posterity Health secured $13 million in Series A funding led by Georgetown Equity Partners, with participation from Distributed Ventures, WVV, and FCA Venture Partners, alongside new investors SteelSky Ventures and Scrub Capital.
Posterity Health has established a partnership with Mark Cuban Cost Plus Drug Company to provide males with access to treatments for infertility, sexual dysfunction, and low testosterone levels.
In 2022, direct-to-consumer healthcare platform Ro acquired male fertility startup Dadi, retiring the brand name to launch the Ro Sperm Kit. This acquisition followed Ro’s earlier purchase of Modern Fertility, demonstrating consolidation within the reproductive health technology sector.
Market Accessibility Focus
The funding reflects growing investor interest in companies addressing male reproductive health, a segment that has historically received less attention than female fertility services. By emphasising mail-in testing and rapid turnaround times, these companies aim to reduce stigma and logistical barriers associated with traditional fertility assessments.
Fellow Health’s laboratory-centric approach differentiates it from competitors focused primarily on telemedicine consultations or fertility tracking applications. The company’s emphasis on clinical partnerships suggests a strategy of integrating with existing healthcare workflows rather than replacing traditional provider relationships.